

Nxera Pharma inks deal with Handok to distribute PIVLAZ in South Korea

16 April 2024 | News

For the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage

Japan-based Nxera Pharma, formerly known as Sosei Group or Sosei Heptares, has entered into an exclusive supply and distribution agreement with Handok Inc. to commercialise PIVLAZ (clazosentan sodium) 150 mg in South Korea.

Under the terms of the agreement, Nxera Pharma Korea will provide drug product to Handok at an agreed price and Handok is exclusively responsible for the promotion, marketing, sales and distribution of PIVLAZ in South Korea. Nxera will receive a one-off upfront payment from Handok upon signing of the agreement and is eligible for further commercial milestone payments plus sales coming from product supply.

PIVLAZ is approved in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH).

Satoshi Tanaka, Dr Med Sci., Executive Officer and Executive Vice President of Nxera, Chairman of NPK, said “We are continuing our long-standing partnership with Handok to bring PIVLAZ to patients in South Korea. PIVLAZ represents a potentially life-changing treatment option for patients and Handok’s wealth of expertise and history of delivering products to the Korean market makes them the ideal partner. With this partnership in place, we are confident that we will be able to deliver PIVLAZ to physicians and patients in South Korea in early 2025.”